Get the Stockscreener App
0.97
7.66%
0.095
Context Therapeutics Inc stock is traded at $0.97, with a volume of 231.37K.
It is up +7.66% in the last 24 hours and up +7.99% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$0.875
Open:
$0.8801
24h Volume:
231.37K
Relative Volume:
1.45
Market Cap:
$86.12M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-1.0659
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
+12.68%
1M Performance:
+7.99%
6M Performance:
+18.49%
1Y Performance:
-51.94%
1-Day Range:
$0.8705
$0.96
1-Week Range:
$0.81
$0.945
52-Week Range:
$0.49
$2.5899
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.96 | 78.49M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
386.74 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.54 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.44 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
726.93 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
338.36 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Analyzing Context Therapeutics Inc. with risk reward ratio chartsPortfolio Performance Summary & Expert Verified Movement Alerts - newser.com
how institutional ownership impacts context therapeutics inc. stockWeekly Profit Recap & Verified Momentum Watchlists - newser.com
Will earnings trigger a reversal in Context Therapeutics Inc.New Guidance & AI Powered Market Trend Analysis - newser.com
Published on: 2025-09-17 04:58:56 - newser.com
Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update - MarketBeat
Analyzing Context Therapeutics Inc. with multi timeframe charts2025 Earnings Impact & Reliable Price Action Trade Plans - newser.com
Real time breakdown of Context Therapeutics Inc. stock performanceJuly 2025 Setups & Free Accurate Trade Setup Notifications - newser.com
How to recover losses in Context Therapeutics Inc. stockWeekly Profit Analysis & Weekly High Return Forecasts - newser.com
Published on: 2025-09-17 02:02:32 - newser.com
Aug Outlook: Can Context Therapeutics Inc. be the next market leader2025 Valuation Update & Long-Term Safe Investment Ideas - خودرو بانک
Aug Final Week: Will Context Therapeutics Inc stock go up in YEARQuarterly Market Summary & AI Driven Stock Reports - خودرو بانک
What data driven models say about Context Therapeutics Inc.’s future2025 Risk Factors & Expert Curated Trade Setups - newser.com
Developing predictive dashboards with Context Therapeutics Inc. dataMarket Performance Report & Daily Stock Momentum Reports - newser.com
Can Context Therapeutics Inc. rally from current levelsInflation Watch & Technical Pattern Alert System - newser.com
Risk Off: Is Context Therapeutics Inc. a strong candidate for buy and holdJuly 2025 Chart Watch & Reliable Breakout Forecasts - خودرو بانک
Fed Watch: Can Context Therapeutics Inc. ride the EV waveDividend Hike & Low Drawdown Investment Ideas - خودرو بانک
Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers - MSN
Is Context Therapeutics Inc. still worth holding after the dipJuly 2025 Opening Moves & Capital Protection Trade Alerts - newser.com
Published on: 2025-09-16 09:03:19 - newser.com
Published on: 2025-09-16 16:44:30 - خودرو بانک
Risk Off: How cyclical is Context Therapeutics Incs revenue stream2025 Growth vs Value & Fast Entry Momentum Alerts - خودرو بانک
Will Context Therapeutics Inc. bounce back from current support2025 Risk Factors & Accurate Intraday Trade Tips - newser.com
Retail Surge: Will Context Therapeutics Inc benefit from government policyWeekly Trade Summary & Breakout Confirmation Trade Signals - خودرو بانک
Value Recap: Can Context Therapeutics Inc stock double in the next yearWeekly Market Report & Long-Term Safe Investment Ideas - خودرو بانک
When is the best time to exit Context Therapeutics Inc.2025 Technical Overview & Fast Momentum Entry Tips - newser.com
Quarterly Recap: Is Nabors Energy Transition Corp II vulnerable to short sellersJuly 2025 Update & Safe Investment Capital Preservation Plans - خودرو بانک
Context Therapeutics Inc. stock trend outlook and recovery pathSwing Trade & Safe Investment Capital Preservation Plans - newser.com
Can a trend reversal in Context Therapeutics Inc. lead to recovery2025 Momentum Check & Smart Swing Trading Techniques - newser.com
Value Recap: How is 3D Systems Corporation managing supply chain issuesJuly 2025 Opening Moves & Weekly Chart Analysis and Trade Guides - خودرو بانک
Earnings Miss: What is the PEG ratio of Context Therapeutics IncJuly 2025 Pullbacks & Intraday High Probability Alerts - خودرو بانک
Trend Review: Is Context Therapeutics Inc. stock suitable for long term investingQuarterly Risk Review & High Conviction Investment Ideas - خودرو بانک
Insider Buy: How does Context Therapeutics Inc compare to its peersWeekly Trade Summary & Growth Focused Stock Pick Reports - خودرو بانک
Using fundamentals and technicals on Context Therapeutics Inc.Swing Trade & Long-Term Safe Investment Ideas - newser.com
Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) Price Target at $5.25 - MarketBeat
Will Context Therapeutics Inc. stock go up soonWeekly Trade Report & Capital Efficient Trading Techniques - newser.com
Applying Wyckoff theory to Context Therapeutics Inc. stockPortfolio Update Summary & Real-Time Volume Analysis - newser.com
Is now a turning point for Context Therapeutics Inc.Market Trend Report & Fast Momentum Stock Entry Tips - newser.com
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Context Therapeutics Inc Stock (CNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
0.03%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):